James Shipley
Overview
Explore the profile of James Shipley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
18
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sabounjian L, Graham P, Wu L, Braman V, Cheng C, Liu J, et al.
Clin Pharmacol Drug Dev
. 2016 Jun;
5(4):314-25.
PMID: 27310332
The prevalence of chronic kidney disease (CKD) related to type 2 diabetes is increasing worldwide. In addition to standard of care, treatment with anti-inflammatory and antifibrotic agents such as CTP-499,...
2.
Braman V, Graham P, Cheng C, Turnquist D, Harnett M, Sabounjian L, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
2(1):53-66.
PMID: 27121560
To determine maximum tolerated dose and food effect for CTP-499, a novel agent being studied for the treatment of diabetic kidney disease. CTP-499 has demonstrated anti-inflammatory, anti-fibrotic and anti-oxidative activities...
3.
Harnett M, Shipley J, MacLean L, Schwiderski U, Sandage Jr B
Clin Drug Investig
. 2012 Dec;
33(2):133-41.
PMID: 23203138
Background: Overactive bladder is a common disorder that affects approximately 34 million adults in the United States. Anticholinergic (antimuscarinic) agents are the most widely used pharmacological option for overactive bladder....
4.
Silver N, Sandage B, Sabounjian L, Schwiderski U, Shipley J, Harnett M
J Clin Pharmacol
. 2009 Dec;
50(2):143-50.
PMID: 19948948
The objective of this study is to characterize the steady-state pharmacokinetics and compare the relative bioavailability of the extended-release capsule formulation of the antimuscarinic trospium chloride, developed for once-daily administration,...